J REIMHERR: Open Payments
NPI 1437178993 · LYNN, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,911 in 185 payments from 17 companies in 2025. Trend: 2023 $7,519 · 2024 $3,045 · 2025 $3,911
Food & beverage: $3,896Education: $14
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $665 |
| ABBVIE INC. | 30 | $531 |
| Neurocrine BioSciences, Inc. | 15 | $393 |
| Lundbeck LLC | 12 | $364 |
| Teva Pharmaceuticals USA, Inc. | 14 | $355 |
| Janssen Pharmaceuticals, Inc | 10 | $330 |
| Alkermes, Inc. | 12 | $250 |
| E.R. Squibb & Sons, L.L.C. | 13 | $241 |
| Axsome Therapeutics, Inc. | 16 | $239 |
| Vanda Pharmaceuticals Inc. | 17 | $218 |
Products named: CAPLYTA, VRAYLAR, REXULTI, INGREZZA, INVEGA SUSTENNA, ARISTADA, COBENFY, Auvelity.
Industry payments across MA — which companies pay providers there.
